Charles River Laboratories International and the Gates Institute at the University of Colorado Anschutz Medical Campus announced a lentiviral vector contract development and manufacturing organization, CDMO, agreement. The Gates Institute mission at the University of Colorado Anschutz Medical Campus is to develop and deliver advanced therapies in cell and gene therapy. Through this strategic collaboration, Gates Institute will have access to Charles River’s established manufacturing platforms and dedicated viral vector CDMO center of excellence, utilizing a range of services including process development evaluation of Gates Institute’s LVV backbone, phase-appropriate research grade and High -Quality plasmid DNA production, and GMP LVV manufacturing. Materials produced within the collaboration will support an upcoming Investigational New Drug application for Phase I clinical trials.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- ‘The CRO Sector Looks Appealing,’ Says Goldman Sachs — Here Are 2 Stocks to Consider
- Charles River, Captain T Cell in plasmid DNA-Viral Vector alliance
- Charles River in collaboration with MatTek awarded $1.3M grant from FCRI
- Charles River initiated with a Neutral at Mizuho
- Dollar Tree downgraded, Lululemon upgraded: Wall Street’s top analyst calls